UB Paderborn / Katalog / Suche / in CDI

Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid

Journal of antimicrobial chemotherapy, 2020-09, Vol.75 (9), p.2605-2608

2020

Volltextzugriff (PDF)

In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus Isolates

Antimicrobial Agents and Chemotherapy, 2010-07, Vol.54 (7), p.3027-3030

2010

Volltextzugriff (PDF)

In Vitro Activities of LTX-109, a Synthetic Antimicrobial Peptide, against Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, Daptomycin-Nonsusceptible, and Linezolid-Nonsusceptible Staphylococcus aureus

Antimicrobial Agents and Chemotherapy, 2012-08, Vol.56 (8), p.4478-4482

2012

Volltextzugriff (PDF)

A case of Gemella morbillorum native valve endocarditis and results of in vitro susceptibility testing

IDCases, 2021-01, Vol.23, p.e01045, Article e01045

2021

Volltextzugriff (PDF)

In Vitro Activity of Retapamulin against Staphylococcus aureus Resistant to Various Antimicrobial Agents

Antimicrobial Agents and Chemotherapy, 2013-09, Vol.57 (9), p.4547-4550

2013

Volltextzugriff (PDF)

In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid

Journal of antimicrobial chemotherapy, 2023-01, Vol.78 (1), p.238-241

2023

Volltextzugriff (PDF)

Broad-Range Bacterial Polymerase Chain Reaction for Early Detection of Bacterial Meningitis

Clinical infectious diseases, 2003-01, Vol.36 (1), p.40-45

2003

Volltextzugriff (PDF)

1588. Delafloxacin Activity Against Staphylococcus aureus with Reduced Susceptibility or Resistance to Methicillin, Vancomycin, Daptomycin, or Linezolid

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S579-S580

2019

Volltextzugriff (PDF)

Rhodomyrtone: a new anti-Staphylococcus aureus agent against resistant strains

JAC-antimicrobial resistance, 2024-07, Vol.6 (4), p.dlae097

2024

Volltextzugriff (PDF)

VISA–Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to Telavancin

Diagnostic microbiology and infectious disease, 2019-02, Vol.93 (2), p.159-161

2019

Volltextzugriff (PDF)

TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus

Antimicrobial agents and chemotherapy, 2015-08, Vol.59 (8), p.4845-4855

2015

Volltextzugriff (PDF)

In Vitro Susceptibilities and Molecular Analysis of Vancomycin-Intermediate and Vancomycin-Resistant Staphylococcus aureus Isolates

Clinical infectious diseases, 2012-08, Vol.55 (4), p.582-586

2012

Volltextzugriff (PDF)

Ceftaroline-Heteroresistant Staphylococcus aureus

Antimicrobial agents and chemotherapy, 2014-06, Vol.58 (6), p.3133-3136

2014

Volltextzugriff (PDF)

In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

International journal of antimicrobial agents, 2010-07, Vol.36 (1), p.69-72

2010

Volltextzugriff (PDF)

Rapid diagnosis of septic arthritis using 16S rDNA PCR: a comparison of 3 methods

Diagnostic microbiology and infectious disease, 2011-04, Vol.69 (4), p.390-395

2011

Volltextzugriff (PDF)

Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus

Journal of antimicrobial chemotherapy, 2007-08, Vol.60 (2), p.406-409

2007

Volltextzugriff (PDF)

Prevalence of colonization with community-associated methicillin-resistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers

Infection control and hospital epidemiology, 2009-01, Vol.30 (1), p.4

2009

Volltextzugriff (PDF)

In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

International journal of antimicrobial agents, 2010-11, Vol.36 (5), p.478-480

2010

Volltextzugriff (PDF)

Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal disease

Infection control and hospital epidemiology, 2006-10, Vol.27 (10), p.1057

2006

Volltextzugriff (PDF)

Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae

International journal of antimicrobial agents, 2005-07, Vol.26 (1), p.81-84

2005

Volltextzugriff (PDF)

Community-Associated Methicillin-Resistant Staphylococcus aureus Causing Chronic Pneumonia

Clinical infectious diseases, 2006-04, Vol.42 (7), p.e57-e60

2006

Volltextzugriff (PDF)

Clinical and laboratory features of community-associated methicillin-resistant Staphylococcus aureus: is it really new?

Infection control and hospital epidemiology, 2006-02, Vol.27 (2), p.133

2006

Volltextzugriff (PDF)

Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae

Journal of antimicrobial chemotherapy, 2001-06, Vol.47 (6), p.875-877

2001

Volltextzugriff (PDF)

Changing epidemiology of community-onset methicillin-resistant Staphylococcus aureus bacteremia

Infection control and hospital epidemiology, 2003-06, Vol.24 (6), p.431

2003

Volltextzugriff (PDF)

In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

International journal of antimicrobial agents, 2010-07, Vol.36 (1), p.69-72

2010

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid

In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus Isolates

In Vitro Activities of LTX-109, a Synthetic Antimicrobial Peptide, against Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, Daptomycin-Nonsusceptible, and Linezolid-Nonsusceptible Staphylococcus aureus

A case of Gemella morbillorum native valve endocarditis and results of in vitro susceptibility testing

In Vitro Activity of Retapamulin against Staphylococcus aureus Resistant to Various Antimicrobial Agents

In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid

Broad-Range Bacterial Polymerase Chain Reaction for Early Detection of Bacterial Meningitis

1588. Delafloxacin Activity Against Staphylococcus aureus with Reduced Susceptibility or Resistance to Methicillin, Vancomycin, Daptomycin, or Linezolid

Rhodomyrtone: a new anti-Staphylococcus aureus agent against resistant strains

VISA–Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to Telavancin

TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus

In Vitro Susceptibilities and Molecular Analysis of Vancomycin-Intermediate and Vancomycin-Resistant Staphylococcus aureus Isolates

Ceftaroline-Heteroresistant Staphylococcus aureus

In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

Rapid diagnosis of septic arthritis using 16S rDNA PCR: a comparison of 3 methods

Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus

Prevalence of colonization with community-associated methicillin-resistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers

In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal disease

Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae

Community-Associated Methicillin-Resistant Staphylococcus aureus Causing Chronic Pneumonia

Clinical and laboratory features of community-associated methicillin-resistant Staphylococcus aureus: is it really new?

Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae

Changing epidemiology of community-onset methicillin-resistant Staphylococcus aureus bacteremia

In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

Suchergebnisse filtern